コンテンツへスキップ
Merck

1138405

USP

プロピオン酸クロベタゾール

United States Pharmacopeia (USP) Reference Standard

ログイン組織・契約価格を表示する


About This Item

実験式(ヒル表記法):
C25H32ClFO5
CAS番号:
分子量:
466.97
MDL番号:
UNSPSCコード:
41116107
PubChem Substance ID:
NACRES:
NA.24

グレード

pharmaceutical primary standard

APIファミリー

clobetasol

メーカー/製品名

USP

アプリケーション

pharmaceutical (small molecule)

フォーマット

neat

保管温度

2-8°C

SMILES記法

CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl

InChI

1S/C25H32ClFO5/c1-5-21(31)32-25(20(30)13-26)14(2)10-18-17-7-6-15-11-16(28)8-9-22(15,3)24(17,27)19(29)12-23(18,25)4/h8-9,11,14,17-19,29H,5-7,10,12-13H2,1-4H3/t14-,17-,18-,19-,22-,23-,24-,25-/m0/s1

InChI Key

CBGUOGMQLZIXBE-XGQKBEPLSA-N

遺伝子情報

human ... NR3C1(2908)

類似した製品をお探しですか? 訪問 製品比較ガイド

詳細

Clobetasol propionate is a fluorinated corticosteroid. It is mainly used as topical ointment. It is an anti-inflammatory agent and has been considered as vasoconstrictor in nature.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

アプリケーション

Clobetasol propionate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Clobetasol Propionate Cream
  • Clobetasol Propionate Ointment
  • Clobetasol Propionate Topical Solution

アナリシスノート

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

その他情報

Sales restrictions may apply.

ピクトグラム

Health hazard

シグナルワード

Danger

危険有害性情報

危険有害性の分類

Aquatic Chronic 4 - Repr. 1B - STOT RE 2

ターゲットの組織

Adrenal gland,Immune system

保管分類コード

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

引火点(°F)

Not applicable

引火点(℃)

Not applicable


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

1138405-200MG:


最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 資料 section.

サポートが必要な場合は、お問い合わせください カスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Marika Kamberi et al.
Journal of chromatographic science, 46(1), 23-29 (2008-01-26)
A novel sensitive high-throughput high-performance liquid chromatography assay is developed and validated for the simultaneous determination of everolimus and clobetasol propionate in pharmaceutical formulations. The chromatographic separation is achieved on a Zorbax Eclipse XDB-C18 reversed-phase column using a gradient elution
J A Carruthers et al.
British medical journal, 4(5990), 203-204 (1975-10-25)
Topical application of clobetasol propionate in a strength of 0-05% in cream or ointment (Dermovate) suppressed the hypothalamic-pituitary-adrenal axis in both normal people and patients with diseased skin. In normal people the 9 am serum cortisol level was suppressed when
S R Wiegell et al.
The British journal of dermatology, 171(6), 1487-1492 (2014-07-26)
Photodynamic therapy (PDT) is an effective and established treatment for actinic keratoses (AK) and nonmelanoma skin cancer. The main side-effects of PDT are post-treatment erythema and oedema, and pain during illumination. Severe erythema after PDT enhances the down time associated
Hetal K Patel et al.
Colloids and surfaces. B, Biointerfaces, 119, 145-153 (2014-04-29)
Vitiligo is a non contagious acquired pigmentation disorder with limited treatment possibilities. Clobetasol propionate (CP) is the drug-of-choice for vitiligo which suppresses the immune system by reducing immunoglobulin action and causes the restoration of melanocytes leading to repigmentation of skin.
Jason E Frangos et al.
Expert opinion on pharmacotherapy, 9(11), 2001-2007 (2008-07-17)
Topical corticosteroids are the most common treatment modality for patients with psoriasis and atopic dermatitis; however, the efficacy of topical corticosteroids is often hampered by barriers to patient adherence, such as lack of efficacy, side effects and inconvenience. Recently published

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)